STAAR Surgical’s shares rose 9.1% following first quarter results driven by solid revenue growth and a return to adjusted EBITDA profitability, with China’s market recovery and U.S. sales milestone leading the upside.

• Net sales grew year-over-year, supported primarily by a strong performance in China and over $6 million in U.S. quarterly sales, a new company milestone.
• Adjusted EBITDA turned positive for the first time in the quarter, reflecting improved operational discipline and margin expansion.
• China normalized inventory levels and demonstrated sustained demand growth for both EVO and newly launched EVO+ ICL lenses.
• FDA approval expanding EVO ICL indications in the U.S. broadens the addressable market, with early signs of increased surgeon adoption.
• Geopolitical and trade disruptions impacted less than $2 million in net sales outside China and the U.S., with ongoing caution in certain regions.